AbbVie
AbbVie announced that IMBRUVICA®
(ibrutinib) was awarded the prestigious Prix Galien 2015 Award for Best Pharmaceutical Agent.
Accelerator Corporation
Accelerator Corporation announced the first closing of Accelerator IV with $51.1 million in capital commitments, as it expands its operations in Seattle to New York City.
Actinium Pharmaceuticals
Actinium Pharmaceuticals announced enrollment in the fourth and final cohort in the Phase 1 portion of the ongoing Phase 1/2 trial of Actimab-A has been completed and that enrollment of the maximum tolerated dose (MTD) confirmatory patients is expected to begin in November.
Adjuvance Technologies Inc
Adjuvance Technologies, Inc., announced that the United States Patent and Trademark Office has granted Adjuvance co-founders a patent for a pioneering invention which provides a novel synthetic method to produce saponin adjuvants including QS-21, a leading vaccine adjuvant currently used in advanced clinical trials for infectious disease, neurodegenerative disorders and oncology.
Albert Einstein College of Medicine
Albert Einstein College of Medicine announced receipt of a 3-year, $750,000 grant from the Congressionally Directed Medical Research Programs (CDMRP), an office of the U.S. Department of Defense (DoD). The funding will support research on the mechanism of action of a novel tumor suppressor protein, FILIP1L, which has been shown to inhibit the spread of ovarian cancer.
Astellas
Pharma Inc
Immunomic Therapeutics, Inc., and Astellas Pharma Inc. announced they have entered into an exclusive worldwide license agreement to the LAMP-vax products for the treatment or prevention of any and all allergic diseases in humans.
Bayer Corporation
Bayer submitted a dossier to the World Health Organization Pesticide Evaluation Scheme (WHOPES) for the evaluation of a new two-way insecticide mixture which includes indoor residual spraying (IRS) against disease vectors.
BioMed Realty Trust, Inc.
Blackstone Group LP agreed to buy landlord BioMed Realty Trust Inc. for $4.8 billion, betting on growth in real estate demand from the life sciences and biotechnology industries.
BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. announced that the first commercial sale of XIAFLEX by Asahi Kasei Pharma Corporation for the treatment of Dupuytren's contracture in Japan has triggered a $1.0 million milestone payment to BioSpecifics.
Bristol-Meyers Squibb
Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.
BlinkBio Inc. (formerly Coferon)
BlinkBio Inc announced that it has entered into a collaboration agreement with Janssen Pharmaceuticals Inc. to accelerate the optimization of prototype leads discovered in the Company's self-assembling dimer program targeting the inhibition of Protein-Protein Interactions.
Chembio Diagnostic Systems, Inc.
Chembio Diagnostics, Inc.,
has been awarded a grant from the Paul G. Allen Ebola Program to develop a POC test to identify multiple life-threatening febrile illnesses.
Children's Tumor Foundation
Children's Tumor Foundation 2012 Clinical Research Award winner, Lei Xu, MD, PhD, of Harvard University, will have her research (Anti-VEGF treatment improves neurological function and augments tumor radiation response in NF2 schwannoma model) published
PNAS.
Chromocell Corporation
Astellas Pharma Inc. and Chromocell Corporation announced that they have entered into a license and collaboration agreement for the development and commercialization of therapeutics to treat neuropathic and other pain conditions.
Cold Spring Harbor Laboratory
On October 14
th
, The Friends of TJ Foundation presented a check for $50,000 to CSHL Associate Professor Chris Vakoc, who is heading the RMS research initiative at Cold Spring Harbor Laboratory as part of CSHL's
Sarcoma Research Project.
Read More
Columbia Business School
"100 Years of Innovation" celebrates Columbia Business School's Centennial, honoring its innovators, past and present.
Columbia College of Physicians and Surgeons
Investigators at Columbia University Medical Center and the Icahn School of Medicine at Mount Sinai have discovered a molecular signaling mechanism that drives a specific type of highly aggressive breast cancer.
Columbia Life Science and Technology Ventures, Columbia University
Kartik Chandran, associate professor of earth and environmental engineering at Columbia Engineering, has been named a 2015 MacArthur Fellow for his work in "transforming wastewater from a pollutant requiring disposal to a resource for useful products, such as commodity chemicals, energy sources, and fertilizers."
Conner Strong & Buckelew
Conner Strong & Buckelew, a leading insurance, risk management and employee benefits brokerage and consulting firm, is proud to announce its participation in the National Youth Entrepreneurship
Challenge.
Cornell Medical Center
Weill Cornell researchers have discovered protein signatures on the membranes of small, tumor-secreted packages containing the blueprint that drives cancers to distant organs
Covington & Burling LLP
Eli Lilly & Company
Eli Lilly and Company expands New York City Research and Development site, moving into an additional 30,000 square feet and adding about 50 new jobs in New York.
Enumeral Biomedical Corp.
Enumeral announced important progress in its anti-PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 and LAG-3 antibody programs.
Ernst & Young LLP
EY and LinkedIn announced a new strategic alliance to jointly offer services to help more companies around the world use technology, social networks and innovative sales techniques to empower their go-to-market efforts.
Girihlet Inc
Girihlet announced that it is one of 15 biotech start-ups to receive funding ($250k/each) from IndieBio (SOSV).
Harlem Biospace
Harlem Biospace announced applications are open for Spring 2016.
Harter, Seacrest & Emery LLP
Harter Secrest & Emery announced that three attorneys have begun practice in the firm's Buffalo office.
HemoGenyx
HemoGenyx has launched a
$200,000 crowdfunding campaign
to fund pre-clinical studies and support the filing of an Investigational New Drug application with the U.S. Food and Drug Administration.
HHMI /The Rockefeller University
The Royal Swedish Academy of Sciences announced that Paul Modrich, a Howard Hughes Medical Institute (HHMI) investigator at Duke University, Tomas Lindahl of the Francis Crick Institute and Clare Hall Laboratory in the UK, and Aziz Sancar of University of North Carolina, Chapel Hill, are the recipients of the 2015 Nobel Prize in Chemistry for mechanistic studies of DNA repair.
Immune Pharmaceuticals Corp.
Immune Pharma Submits IND in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid.
Intensity Therapeutics, Inc.
The Board of Kuala Innovations Limited
announced that it has subscribed for a 3.5 per cent. interest in Delaware incorporated private company Intensity Therapeutics, Inc.
Read More
International AIDS Vaccine Initiative
The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.
Intra-Cellular Therapies, Inc
Intra-Cellular Therapies, Inc.,
announced positive results from the first Phase 3 clinical trial of ITI-007 for the treatment of patients with schizophrenia.
IRX Therapeutics, Inc
PCT, LLC announced that it will expand its current manufacturing capacity at PCT's Allendale, New Jersey, facility to support IRX Therapeutics's anticipated clinical trial manufacturing needs for the INSPIRE Phase 2b study in head and neck cancer patients.
Medidata Solutions
MetaStat, Inc.
MetaStat announced reverse stock split in preparation for a proposed uplisting to a national market.
Mintz Levin
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. added to its Intellectual Property team in Washington, D.C. with Mark Pino, a leading attorney in the pharmaceutical, biotechnology, and chemical areas
Moses & Singer LLP
Moses & Singer announced that a total of 41 attorneys were chosen for distinction in the 2015 Metro Edition of New York Super Lawyers®.
New York Blood Center, Inc
New York Blood Center (NYBC) and the Howard and Abby Milstein Foundation announced a further expansion of their collaborative efforts to advance the use of specialized stem cell lines in regenerative medicine.
New York City College of Technology
City Tech congratulates Professor Robert Russo, chair of the Department of Vision Care Technology, who received the National Academy of Opticianry "Joseph Bruneni Memorial Education Achievement Award."
New York Genome Center
The New York Genome Center announced that it was awarded a National Heart, Lung and Blood Institute Whole Genome Sequencing and Omics Project for the Trans-Omics for Precision Medicine Program contract of $13.5 million dollars for large-scale whole genome sequencing.
The New York Stem Cell Foundation
The New York Stem Cell Foundation (NYSCF) announced the 2015 class of NYSCF - Robertson Investigators, selecting five of the most talented scientists.
Each Investigator will receive a $1.5 million award, disbursed over the next five years.
New York University Langone Medical Center
New studies by researchers at NYU Langone Medical Center show that insulin plays a much stronger role than previously known in regulating release of dopamine, a neurotransmitter that helps control the brain's reward and pleasure centers.
New York Presbyterian Hospital
Early data from a NewYork-Presbyterian/Columbia pilot study suggests that an innovative microsurgery technique helps prevent lymphedema in breast cancer patients. Results from the study have been published in the Annals of Surgical Oncology.
Novomer LLC
Novomer announced that Jowat AG is the first to commercially adopt Novomer's new Converge® polypropylene carbonate (PPC) polyols for use in polyurethane hot melt adhesive applications.
Ophthotech Corporation
Ophthotech Corporation
announced the completion of patient recruitment for its second Phase 3 trial of Fovista® (pegpleranib) in combination with Lucentis® (ranibizumab) for the treatment of wet age-related macular degeneration (AMD).
Optologix LLC
Dr. Gardner, CSO of Optologix, is featured in an interview by
ASBMB Today
.
Pfizer, Inc.
Pfizer Inc. announced the completion of an agreement with Protalix in which Pfizer
will expand its support of ELELYSOTM (taliglucerase alfa) for the
Gaucher community.
Read More
PricewaterhouseCoopers LLP
PwC US announced the appointment of David Ethridge to Managing Director in the firm's Deals practice and U.S. IPO Services leader.
Progenics Pharmaceuticals Inc.
Valeant Pharmaceuticals International
, Inc., and
Progenics Pharmaceuticals, Inc.,
announced that the
U.S. Food and Drug Administration
(FDA) has accepted for review Valeant's New Drug Application for RELISTOR® (methylnaltrexone bromide) Tablets.
Prophylix Pharma will take its novel prophylactic NAITgam intoPhase I/II trials in Q3 2015. NAITgam protects newborns against therare but potentially crippling and fatal bleeding disorder calledFetal and Neonatal Alloimmune Thrombocytopenia (FNAIT).
Provista Diagnostics Inc.
Provista Diagnostics, Inc., announced the reelection of the company's Board of Directors.
PGI Drug Discovery LLC (PsychoGenics) announced that the Company has extended its drug discovery and development collaboration with Sunovion Pharmaceuticals, Inc., for another four years.
Purdue Pharma, L.P.
Purdue Pharma L.P. and AnaBios Corporation announced the intent to form a joint venture aimed at accelerating the development of Purdue Pharma's Nav1.7 sodium ion channel compounds for the treatment of chronic pain. The joint research and development effort would leverage Purdue Pharma's intellectual property and lead compounds, combined with AnaBios' Phase-X® technology.
Regeneron Pharmaceuticals Inc.
Icahn School of Medicine at Mount Sinai and Regeneron announce new antibody research agreement.
The Research Foundation of SUNY
An enigmatic RNA gene is being studied by a University at Albany Cancer Research Center post-doctoral associate, Rebecca Sinnott DeVaux, as a tool to distinguish aggressive from indolent breast cancers and identify why some breast cancers become life-threatening metastasis.
The Rockefeller University
A team of researchers from The Rockefeller University, Brookhaven National Laboratory, and Stony Brook University has revealed the molecular architecture of the DNA replisome.
Signal Genetics, Inc.
Signal Genetics, Inc.
, announced the signing of additional preferred provider organization (PPO) agreements.
Slone Partners
Slone Partners announced the placement of Dr. Richard Bender as Chief Medical Officer at Signal Genetics, Inc., a commercial stage, molecular genetics diagnostic company.
SUNY Downstate Medical Center
The State University of New York announced $530,000 in funding for two collaborative research projects involving SUNY Downstate Medical Center, the University at Buffalo, and Stony Brook University that will advance understanding of the human brain as part of the SUNY Brain Network of Excellence.
University of Albany, SUNY
University at Albany President Robert J. Jones joined Senator Chuck Schumer (D-NY) and Blackstone Charitable Foundation President and Chief Operating Officer Tony James in New York City to announce the expansion of the Blackstone LaunchPad entrepreneurship program to the University and four New York State universities.
University of Rochester
The Center for Emerging and Innovative Sciences (CEIS) at the University of Rochester has been renewed by New York State as one of its Centers for Advanced Technology (CAT) and will receive $9.2 million in funding over the next 10 years.
Weill Cornell Medical College
A new therapeutic approach that targets an aggressive form of lymphoma may greatly increase the efficacy of treatment and result in better outcomes for patients, according to new research by scientists at Weill Cornell Medicine.
White & Case
White & Case LLP and Mergermarket released a new report, "The Cutting Edge: Shaping the Future of Digital Healthcare," which surveyed US-based senior-level executives in the life sciences and technology fields about their views of the future of digital healthcare and the obstacles they may need to overcome to successfully develop digital healthcare products and services.
Willis HRH
Willis Group Holdings plc
announced the completion of its acquisition of
PMI Health Group
, a leading independent healthcare adviser and broker in the
UK
.
WISE
WISE has received the 'BtoB Award 2015' (start up section), organized by Hubnet.
